2017 American Transplant Congress » Poster Session A: Viral Conundrums

5:30pm-7:30pm

ASP0113 Elicits an Immune Response in CMV-Seronegative Dialysis Patients: Comparison to Healthy Subjects.

P. Bonate,¹ C. Van Sant,² K. Cho,¹ E. Zook,¹ L. Smith,³ S. Boutsaboualoy, X. Wang,¹ R. Wu,¹ A. Koester,⁴ D. Rammelsberg,⁶ R. Goldwater,⁴ T. Marbury.⁵

5:30pm-7:30pm

Ambiguous Nucleic Acid Tests (NAT) Results – Case of a Donor with Intermittent HCV NAT(+) but No HCV Transmission.

M. Nowicki,^1,2 H. Prince,² C. Chinchilla,² C. De Los Santos,² J. Trageser,³ L. Stocks.³

5:30pm-7:30pm

Antiretroviral Therapy Modification of HIV+ Patients Listed for Kidney Transplantation.

D. Lee,¹ G. Malat,³ T. Bias,¹ S. Epstein,¹ L. Levin Mizrahi,² M. Harhay,² S. Talluri,² K. Ranganna.²

5:30pm-7:30pm

CMV Infection in Renal Transplant Recipients: Incidence and Efficacy of Prophylaxis According to Cytokine Single Nucleotide Polymorphisms.

I. Perez-Flores, M. Moreno De La Higuera, N. Calvo Romero, B. Rodriguez Cubillo, A. Shabaka, M. Calvo Arevalo, V. Lopez De La Manzanara, A. Sanchez-Fructuoso.

5:30pm-7:30pm

Cytomegalovirus Renal Infection: Rare Manifestation of a Common Post-Transplant Viral Infection — A Case Series.

M. Posadas Salas, J. Thompson, T. Ngo, S. Self.

5:30pm-7:30pm

Cytomegalovirus Viral Load: Characterization of Results from Clinical Specimens.

S. Kleiboeker.

5:30pm-7:30pm

Does EBV Viremia at Time of Transplant Have a Negative Impact on Transplant Outcomes?

P. Verghese, H. Balfour, D. Schmeling, J. Grimm, S. Chinnakotla, A. Matas.

5:30pm-7:30pm

Effect of Influenza Vaccination in the Severity of Illness in Hospitalized Transplant Recipients with Laboratory-Confirmed Influenza.

A. Bagenski,¹ F. Silveira.²

5:30pm-7:30pm

Eight Years of Low-Dose Valganciclovir; Evaluating the Incidence and Risk Factors of CMV in Kidney Transplant Recipients.

S. El Hajj, M. Kim, J. Azzi, S. Gabardi.

5:30pm-7:30pm

Emerging Variables Which May Enhance Care of HIV Positive Renal Transplant Recipients.

D. Leonard, M. Prendergast.

5:30pm-7:30pm

Evaluation of Immunological States of Patients with Cytomegalovirus Infection After Kidney Transplantation.

A. Tanaka, K. Ide, Y. Tanaka, K. Ishiyama, M. Ohira, H. Tahara, S. Shimizu, D. Kumar, H. Ohdan.

5:30pm-7:30pm

Ganciclovir Resistant Cytomegalovirus Infection in Abdominal Tansplant Recipients.

J. Fose, M. Jorgenson, K. Rolling, E. McCreary, D. Mandelbrot, J. Smith.

5:30pm-7:30pm

High-Dose Acyclovir for Cytomegalovirus Prevention in Seropositive Solid Organ Transplant Recipients.

J. Fose,¹ E. McCreary,¹ M. Jorgenson,¹ M. Lucey,² J. Smith.²

5:30pm-7:30pm

High-Risk Human Papillomavirus Associated with Genital Squamous Cell Carcinoma in Nonwhite Organ Transplant Recipients.

K. Nadhan,¹ M. Larijani,¹ L. Ogrich,¹ C. Shaver,¹ A. Doyle,² C. Chung.¹

5:30pm-7:30pm

Immediate vs Delayed Initiation of CMV Prophylaxis…Safe and Cost Beneficial?

L. Cotiguala, A. Carlson, C. Truax, B. Sirandas, I. Hall, L. Smith.

5:30pm-7:30pm

Impact of Timeliness of Assessment of Positive Cytomegalovirus Polymerase Chain Reaction Results in Abdominal Organ Transplant Recipients.

K. Roach, H. Triemer, M. Hurtik, A. Mehta.

5:30pm-7:30pm

Improving Donor Screening for Cytomegalovirus (CMV): Is CMV IgG Avidity Better Than CMV IgM?

H. Prince,¹ M. Nowicki.^1,2

5:30pm-7:30pm

Incidence of Cytomegalovirus Infection Among Liver Transplant Recipients Maintained on a Cyclosporine vs. Tacrolimus-Based Immunosuppression Regimen.

C. Burrelli, M. Bradley, S. Pouch, E. Elkhammas, H. Winters.

5:30pm-7:30pm

Kidney Transplantation in HCV+ Recipients in a New Era of Diagnostics and Therapeutics.

C. Traynor, S. Bumb, C. Berg, M. Ellis, J. Roberts, A. Muir, L. King, C. Brady, S. Sanoff.

5:30pm-7:30pm

Kinetics of Cytomegalovirus (CMV) DNAemia in CMV Mismatch Solid Organ Transplant Patients with Primary CMV Infection.

C. Hernandez, D. Chiang, S. Fuentes, C. Cervera.

5:30pm-7:30pm

Lack of Specificity of LC-MS/MS Based Urinary Biomarkers for Polyomavirus BK Nephropathy (BKPyVN).

G. Zeng,¹ L. Pan,² Z. Lyu,² Y. Huang,¹ P. Randhawa.¹

5:30pm-7:30pm

Low Incidence of Acute Rejection within the Six Months After Transplantation in HIV Recipients Treated with Raltegravir, the ANRS 153 Treve Trial.

M. Matignon,¹ A. Lahiani,⁹ J. Lelievre,² D. Desvaux,⁶ K. Abassi,⁹ A. Diallo,⁹ M. Peraldi,⁷ A. Taburet,⁴ J. Saillard,⁵ C. Delaugerre,³ L. Assoumou,⁹ P. Grimbert,¹ TREVE ANRS Study Group.⁵

5:30pm-7:30pm

Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate Risk Renal Transplants: A Single Center Experience.

A. Baghban,¹ K. Belfield,² M. Azar,¹ E. Cohen,² M. Malinis.¹

5:30pm-7:30pm

Measles Screening and Vaccination in Solid Organ Transplant Recipients: Adherence to Infectious Disease Community of Practice (IDCOP) Recommendations.

F. Irani,¹ R. Butler,² C. Kovacs.

5:30pm-7:30pm

Nonmelanoma Skin Cancer Rates Are Not Affected by Chronic HIV(+) or HCV(+) Infection in Organ Transplant Recipients.

K. Nadhan, E. Usedom, S. Shipman, A. Doyle, G. Malat, E. Buchanan, C. Chung.

5:30pm-7:30pm

Pharmakokinetics of Daclatasvir, Sofosbuvir and GS-331007 in a Prospective Cohort of HCV Positive Kidney Transplant Recipients.

E. Schrezenmeier,¹ P. Galander,¹ F. Hoffmann,² C. Jaeger,² J. Lisec,² J. Schrezenmeier,² O. Staeck,¹ L. Lehner,¹ D. Khadzhynov,¹ F. Halleck,¹ M. Duerr,¹ K. Budde.¹

5:30pm-7:30pm

Rates of CMV Infection in Kidney Transplant Recipients Who Received Subtherapeutic Valganciclovir Prophylaxis.

K. Belfield, E. Cohen, M. Malinis, A. Baghban.

5:30pm-7:30pm

Reproducibility of the Cobas CMV Test (cobas CMV) and Clinical Concordance with the Cobas Ampliprep / Cobas TaqMan CMV Test (CAP/CTM CMV).

P. Baum,¹ J. Yao,² A. Butcher,¹ P. Hemyari,¹ A. Valsamakis,³ S. Young.⁴

5:30pm-7:30pm

Risk Factor for Hepatitis E Virus Infection Among Solid-Organ-Transplant Patients.

N. Kamar,¹ S. Lhomme,² F. Abravanel,² L. Esposito,¹ A. Hebral,¹ O. Marion,¹ A. Del Bello,¹ J. Izopet.²

5:30pm-7:30pm

Risk Factors for Polyomavirus Infection After Renal Transplantation: Introduction of the Protective Effect of Peritoneal Dialysis.

S. Hosseini-Moghaddam, Q. Xu, J. Kum, H. Alharbi, A. Jevnikar, M. John, G. Singh, S. Parsons, M. Edgar, P. Luke.

5:30pm-7:30pm

Sequential Monitoring of Natural Killer Cell Reconstitution Against CMV Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation.

P. Ki Hyun,¹ L. Hyeyoung,² R. Ji Hyeong,¹ K. Yonggoo,² H. Kyungja,² C. Byung Sik,² K. Hee-Je,³ M. Woosung,³ O. Eun-Jee.²

5:30pm-7:30pm

Single-Center Initial Experience in Treating Chronic Hepatitis C in Kidney Transplant Recipients.

G. Meinerz, C. da Silva, R. Bruno, E. Keitel, V. Garcia.

5:30pm-7:30pm

The Evolution of Hepatitis B Surface Antibody (Anti-HBs) Titer of the Kidney Transplant Recipients: A 5-Year Experience Guideline for the Optimal Maintaining Immunization.

W. Chancharoenthana, A. Leelahavanichkul, S. Wattanatorn, Y. Avihingsanon, K. Praditpornsilpa, N. Townamchai.

5:30pm-7:30pm

The Impact of Hepatitis C Treatment on GFR and Immunosuppression in Renal Transplant Recipients.

J. Husson, R. Adekunle, B. Ravichandran, P. Mathur, S. Jonchhe, K. Stafford.

5:30pm-7:30pm

Usefulness of Valacyclovir Prophylaxis for Preventing Cytomegalovirus Infection After Anti-Thymocyte Globulin Treatment as Antirejection Therapy.

E. Ko,^1,2 J. Yu,^1,2 B. Choi,^1,2 C. Park,^1,2 Y. Kim,^1,2 C. Yang,^1,2 B. Chung.^1,2

5:30pm-7:30pm

Utility of “High-Dose” Ganciclovir in High Viral Load CMV Infection in Transplant Recipients.

M. Alfares, R. Avery, N. Turki, K. Alfares, S. Mehta, R. Boger, A. Valsamakis.

5:30pm-7:30pm

Willingness of End-Stage Renal Disease Patients (ESRD) without Hepatitis C (HCV) to Accept a HCV+ Kidney.

P. Reese,¹ D. Goldberg,¹ A. Mussell,¹ M. McCauley,¹ D. Sawinski,¹ N. Molina,² R. Tomlin,² S. Doshi,¹ P. Abt,¹ E. Blumberg,¹ C. Thiessen,² S. Kulkarni,² G. Esnaola.²

5:30pm-7:30pm

Willingness to Donate Organs Among Persons Living with HIV.

S. Halpern, K. Kumar, A. Nguyen, S. Rasmussen, S. Anjum, A. Massie, A. Tobian, D. Segev, J. Sugarman, C. Durand.